Board of Directors

Elizabeth LR Donley, JD MBA MS
Chief Executive Officer
Ms. Donley brings a unique combination of business and legal experience to Stemina. She has more than twenty years of experience in intellectual property, law, and business management. Ms. Donley served as General Counsel and Director of Business Development for the Wisconsin Alumni Research Foundation (WARF) for more than eight years.
During those eight years, Ms. Donley negotiated hundreds of licenses and sponsored research and collaboration agreements between industry and WARF, the intellectual property management organization for the University of Wisconsin. Ms. Donley also served as Managing Director of both WARF subsidiaries: WiSys Technology Foundation (WiSys) and WiCell Research Institute (WiCell).
WiCell distributes human embryonic stem (hES) cells, trains researchers worldwide and conducts important research involving many aspects of hES cell research. In 2005, WiCell was awarded a $16 million contract by the National Institute of Health to serve as the National Stem Cell Bank.
Prior to joining WARF in 1998, Ms. Donley practiced law with the law firm of Quarles & Brady in the areas of intellectual property law, business transactions, securities, and corporate law.
Elizabeth LR Donley, JD MBA MS
Chief Executive Officer

Barbara L. Handelin, PhD
Barbara L. Handelin, PhD
CEO – Audacity Therapeutics, PBC

Don M. Hardison
Don M. Hardison
President, CEO and Director - Biotheranostics, Inc.

Andrew Morgan, R.Ph.
Executive Vice President, Regulatory Affairs & Quality Operations – Zurex Pharma
Before joining Genzyme, Mr. Morgan served as the Vice President of Regulatory, Quality, and Pharmaceutical Sciences at Bone Care International in Middleton until the company’s acquisition by Genzyme in 2005. Prior to joining Bone Care, he was the Director of Regulatory Affairs for Celltech Pharmaceuticals, Inc. in Rochester, New York. Before joining Celltech, he was the manager of regulatory affairs for Medeva Pharmaceuticals in Fort Worth, Texas. He has over 25 years of experience helping lead pharmaceutical companies while being responsible for regulatory, quality, development, and manufacturing activities. Andrew currently serves as a Pharmaceutical Catalyst on the Wisconsin Alumni Research Foundation (WARF) Accelerator Program. Mr. Morgan, a registered pharmacist, received his Bachelor of Science of Pharmacy degree from SWOSU School of Pharmacy in Weatherford, Oklahoma.
Andrew Morgan, RPh
Executive Vice President, Regulatory Affairs and Quality Operations – Zurex Pharma

Marc Schneebaum
Marc Schneebaum
SVP and Chief Financial Officer - Avlyan Pharmaceuticals
